High Growth Tech Stocks In Asia To Watch April 2026

As global markets navigate geopolitical tensions and economic shifts, the Asian tech sector continues to capture investor interest with its potential for high growth, particularly as technology stocks in Japan and China show resilience amid broader market fluctuations. In this evolving landscape, identifying promising tech stocks often involves assessing their ability to leverage advancements in artificial intelligence and infrastructure spending while managing external risks such as energy price volatility.

Top 10 High Growth Tech Companies In Asia

Click here to see the full list of 119 stocks from our Asian High Growth Tech and AI Stocks screener.

Let’s explore several standout options from the results in the screener.

Simply Wall St Growth Rating: ★★★★★★

Overview: CARsgen Therapeutics Holdings Limited is an investment holding company focused on the discovery, development, and commercialization of CAR-T cell therapies for treating hematological malignancies, solid tumors, and autoimmune diseases in China, with a market cap of approximately HK$11.74 billion.

Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to CN¥125.66 million. With a focus on CAR-T cell therapies, it addresses hematological malignancies, solid tumors, and autoimmune diseases in China.

CARsgen Therapeutics Holdings has demonstrated a robust trajectory in the competitive biotech landscape, particularly in the CAR T-cell therapy sector. With a significant 64.2% annual revenue growth, the company outpaces the Hong Kong market’s average of 8.6%. This growth is complemented by an expected earnings surge of 83.56% annually, highlighting its rapid advancement despite current unprofitability. Recent strategic alliances, like the establishment of a new manufacturing base with Shanghai Jingong Enterprise involving an investment up to RMB 370 million, underscore its commitment to scaling operations and enhancing global competitiveness without heavy initial capital expenditure—preserving cash flow for pivotal R&D and market expansion efforts. These moves not only align with national biopharmaceutical policies but also position CARsgen to potentially lead in global markets, reflecting strong future prospects as it navigates towards profitability anticipated within three years.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: China National Software & Service Company Limited, along with its subsidiaries, offers basic software and core application solutions both domestically and internationally, with a market cap of approximately CN¥34.52 billion.

Operations: The company generates revenue primarily through its Software Service Business, amounting to CN¥5.17 billion.

China National Software & Service has shown resilience in a challenging market, with its first-quarter revenue rising to CNY 709.49 million from CNY 640.5 million year-over-year, despite a net loss decrease to CNY 73.72 million from CNY 80.62 million. This performance is part of a broader trend where the company’s revenue growth rate stands at an impressive 18.5% annually, outpacing the Chinese market average of 15.3%. Looking ahead, the firm is expected to pivot into profitability within three years, boasting an anticipated earnings growth of 115.44% per year, supported by positive free cash flow dynamics and strategic initiatives that align with evolving market demands in high-tech sectors across Asia.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shenzhen Kaifa Technology Co., Ltd. offers electronics manufacturing services globally and has a market cap of CN¥45.94 billion.

Operations: Shenzhen Kaifa Technology Co., Ltd. delivers a range of electronics manufacturing services to a global clientele. The company focuses on diverse revenue streams, including the production and assembly of electronic components and devices.

Shenzhen Kaifa Technology has demonstrated robust growth, with its annual revenue surging by 26.9% and earnings by an impressive 32.4%. This performance is underscored by a significant R&D commitment, allocating CNY 1.2 billion last year, representing about 7.6% of their total revenue, signaling a strong focus on innovation in the competitive tech landscape of Asia. Despite a recent dip in first-quarter sales to CNY 528.83 million from CNY 809.73 million the previous year, the company’s strategic investments in technology development may well position it for future recovery and growth in high-demand sectors such as electronic manufacturing services for global tech giants.

Make It Happen

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:2171 SHSE:600536 and SZSE:000021.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com